Lamotrigine

Lamotrigine may be associated with increased risk of cardiac arrhythmias, FDA warns

By Saadia Aslam An FDA review of study findings showed a potential increased risk of cardiac arrhythmias in patients with pre-existing cardiac disease who are…

View More Lamotrigine may be associated with increased risk of cardiac arrhythmias, FDA warns
Erythromycin pills

Erythromycin: Caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban

Drug Safety Update Published 17 December 2020From: Medicines and Healthcare products Regulatory Agency Erythromycin has been associated with events secondary to QT interval prolongation such…

View More Erythromycin: Caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban